MAPK3 and non-small cell lung carcinoma: In this study, ERK1/2 inhibition, achieved by different ERK1/2 inhibitors including ravoxertinib (GDC0994) and ulixertinib (BVD-523 or VRT752271), combined with osimertinib synergistically decreased the survival of osimertinib-resistant NSCLC cell lines and effectively inhibited the growth of osimertinib-resistant xenografts in nude mice.